IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 251-275 out of 1265.

<< < 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 > >>

Public Release: 19-Nov-2014
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Researchers identify biological indicator of response to new ovarian cancer drug
Researchers have found how to identify which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib. Clinical trials have shown that women with platinum-based chemotherapy-sensitive tumours, who carry inherited mutations in the BRCA1/2 genes respond well to rucaparib. But in new findings presented at the 26th EORTC-NCI-AACR Symposium, researchers say that they have identified a biological indicator that can predict which women without BRCA1/2 mutations will respond to the drug.
Clovis Oncology

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 19-Nov-2014
American Heart Association's Scientific Sessions 2014
Common blood pressure medication does not increase risk of breast cancer, study finds
Women who take a common type of medication to control their blood pressure are not at increased risk of developing breast cancer due to the drug, according to new study by researchers at the Intermountain Medical Center Heart Institute in Murray, Utah.

Contact: Jess C. Gomez
jess.gomez@imail.org
801-507-7455
Intermountain Medical Center

Public Release: 19-Nov-2014
Science Translational Medicine
Salk scientists deliver a promising one-two punch for lung cancer
A combination of two unexpected drugs targets tumors.

Contact: Salk Communications
press@salk.edu
Salk Institute

Public Release: 18-Nov-2014
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
First demonstration of anti-cancer activity for an IDH1 mutation inhibitor
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukaemia with the IDH1 mutation. Professor Daniel Pollyea will tell the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that early results from the phase 1 clinical trial of the drug AG-120 have been encouraging.
Agios Pharmaceuticals

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 18-Nov-2014
Biophysical Journal
New computational model could design medications like chemotherapy with fewer side effects
Medications, such as chemotherapy, are often limited by their tendency to be detrimental to healthy cells as an unintended side effect. Now research in the Nov. 18 issue of Cell Press's Biophysical Journal offers a new computational model that can help investigators design ways to direct drugs to their specific targets.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 18-Nov-2014
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Galeterone shows activity in a variant form of castration-resistant prostate cancer
Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy (castration-resistant prostate cancer or CRPC). The 26th EORTC-NCI-AACR Symposium will hear that galeterone was well tolerated by patients in the ARMOR2 trial, and lowered PSA levels in men with CRPC that was resistant to other drugs that target the cancer.
Tokai Pharmaceutical

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 18-Nov-2014
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. The 26th EORTC-NCI-AACR Symposium will hear that the combination of bevacizumab and erlotinib produced excellent response rates in patients with advanced papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer.
Genentech

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 18-Nov-2014
PLOS Biology
Cells' natural response to chronic protein misfolding may do more harm than good
'Protein misfolding' diseases such as cystic fibrosis and Alzheimer's may be seriously exacerbated by the body's own response against that misfolding, according to a new study led by scientists at The Scripps Research Institute.
Cystic Fibrosis Foundation Therapeutics, National Institutes of Health, WKZ Research Fund, NCFS HIT-CF program, American Health Assistance Foundation, Australia's National Health and Medical Research Council, Canadian Cystic Fibrosis Foundation

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 18-Nov-2014
Nature Communications
Two sensors in one
MIT chemists have developed new nanoparticles that can simultaneously perform magnetic resonance imaging and fluorescent imaging in animals.
National Institutes of Health, US Department of Defense, National Science Foundation, Koch Institute for Integrative Cancer Research

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology

Public Release: 18-Nov-2014
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Trial shows treatment-resistant advanced non-small cell lung cancer responds to rociletinib
A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer, but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial. The research will be presented at the 26th EORTC-NCI-AACR Symposium meeting in Barcelona, Spain.
Clovis Oncology

Contact: Emma Mason
wordmason@mac.com
44-137-656-3090
ECCO-the European CanCer Organisation

Public Release: 18-Nov-2014
Nature Chemistry
Finding new ways to make drugs
Chemists have developed a revolutionary new way to manufacture natural chemicals by clipping smaller molecules together like Lego. They have used the new method to assemble a scarce anti-inflammatory drug with potential to treat cancer and malaria, pseudopterosin.

Contact: Michael Sherburn
michael.sherburn@anu.edu.au
61-261-254-988
Australian National University

Public Release: 17-Nov-2014
Nature Genetics
UTSW cancer researchers identify gene mutations and process for how kidney tumors develop
Using next generation gene sequencing techniques, cancer researchers at University of Texas Southwestern Medical Center have identified more than 3,000 new mutations involved in certain kidney cancers, findings that help explain the diversity of cancer behaviors.
Genentech Inc.

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 17-Nov-2014
Journal of Clinical Investigation
A noncoding RNA promotes pediatric bone cancer
Ewing sarcoma is a cancer of bone or its surrounding soft tissue that primarily affects children and young adults. A new study in the Journal of Clinical Investigation indicates that a long non-coding RNA named Ewing sarcoma-associated transcript 1 contributes to the complex network of changes that occur in Ewing Sarcoma.
Doris Duke Clinical Scientist Development Fund, St. Baldrick's Foundation, Kavner Family Fund, Hope Street Kids Foundation, Sunbeam Foundation, Elsa U. Pardee Foundation, Bear Necessities Foundation, Hyundai Hope on Wheels

Contact: Corinne Williams
press_releases@the-jci.org
919-684-0620
Journal of Clinical Investigation

Public Release: 17-Nov-2014
Annals of Internal Medicine
Need to encourage patients to screen for colon cancer? Try a lottery
Convincing patients to do an often dreaded colon cancer screening test could just take a little extra nudge -- like a chance to win $50.
VA Center for Health Equity Research and Promotion, Robert Wood Johnson Foundation

Contact: Beata Mostafavi
bmostafa@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 17-Nov-2014
Proceedings of the National Academy of Sciences
The dirty side of soap
Triclosan is an antimicrobial commonly found in soaps, shampoos, toothpastes and many other household items. Despite its widespread use, researchers at University of California, San Diego School of Medicine report potentially serious consequences of long-term exposure to the chemical.
US Public Health Service

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 17-Nov-2014
Nature Medicine
Potential therapy found for incurable pediatric brain tumor
scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer. By inhibiting the tumor-forming consequences of the mutation using an experimental drug called GSKJ4, they delayed tumor growth and prolonged survival in mice with pediatric brainstem glioma.
National Institutes of Health

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University

Public Release: 17-Nov-2014
Proceedings of the National Academy of Sciences
First genetic-based tool to detect circulating cancer cells in blood
Northwestern University scientists have demonstrated the first genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood -- no easy feat. The NanoFlare technology potentially could detect cancer cells long before they could settle somewhere in the body and form a dangerous tumor. In a breast cancer study, the NanoFlares easily entered cells and lit up the cell if a biomarker target was present, even if only a trace amount.
NIH/National Cancer Institute, National Institutes of Health, American Cancer Society, Air Force Office of Scientific Research, Howard Hughes Medical Institute

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 17-Nov-2014
ecancermedicalscience
The secret life of anti-cancer drugs
The public is bombarded with news of exciting developments in cancer research every day, with new anti-cancer drugs greeted with excitement. In a new review published in ecancermedicalscience, researchers trace the journey anti-cancer drugs take between discovery and clinical practice.

Contact: Katie Foxall
katie@ecancer.org
01-179-420-852
ecancermedicalscience

Public Release: 17-Nov-2014
Lancet Oncology
Investigational oral drug combo shows promise for newly diagnosed multiple myeloma
The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.
Millennium Pharmaceuticals

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 17-Nov-2014
American Journal of Public Health
UTHealth smoking study: Financial incentives double quit rates
Offering small financial incentives doubles smoking cessation rates among socioeconomically disadvantaged smokers, according to research from the University of Texas Health Science Center at Houston.
American Cancer Society, University of Texas Health Science Center at Houston

Contact: Hannah Rhodes
Hannah.C.Rasorrhodes@uth.tmc.edu
713-500-3053
University of Texas Health Science Center at Houston

Public Release: 17-Nov-2014
Journal of Thoracic Oncology
Race, hospital, insurance status all factors in how lung cancer is treated
African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology.

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago

Public Release: 17-Nov-2014
Environmental Science & Technology
'Probiotics' for plants boost detox abilities; untreated plants overdose and die
Scientists using a microbe that occurs naturally in eastern cottonwood trees have boosted the ability of two other plants -- willow and lawn grass -- to withstand the withering effects of the nasty industrial pollutant phenanthrene and take up 25 to 40 percent more of the pollutant than untreated plants.
NIH/National Institute of Environmental Health Sciences, Byron and Alice Lockwood Endowed Professorship

Contact: Sandra Hines
shines@uw.edu
206-543-2580
University of Washington

Public Release: 17-Nov-2014
Mayo Clinic Proceedings
Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye
One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called tumor necrosis factor inhibitors. They act by dampening part of the immune system called tumor necrosis factor. In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of eye cancer, uveal melanoma. Mayo Clinic researchers make the case and alert physicians in an article in Mayo Clinic Proceedings
Terrance and Judi Paul, Research to Prevent Blindness, Inc

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 17-Nov-2014
Nature
Metabolic 'reprogramming' by the p53 gene family leads to tumor regression
Scientists have found that altering members of the p53 gene family, known as tumor suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 17-Nov-2014
Cell Reports
Side effects of possible anti-cancer strategy discovered
The Malt1 protein is one of the most important control centers in human immune cells and a real all-rounder. Genetic defects in it can lead to the development of lymphatic cancer (lymphoma). A possible therapeutic approach is therefore to specifically block certain functions of Malt1, thus destroying the cancer cells. Now, however, scientists at Technische Universität München have shown in a mouse model that such a blockade can cause serious side effects.

Contact: Vera Siegler
vera.siegler@tum.de
49-892-892-2731
Technische Universitaet Muenchen

Showing releases 251-275 out of 1265.

<< < 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 > >>

  Search News Releases

     

 

EurekAlert!